NasdaqGS - Delayed Quote • USD
argenx SE (ARGX)
At close: 4:00 PM EDT
After hours: 4:26 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 21 | 20 | 26 | 25 |
| Avg. Estimate | -0.76 | -0.79 | -2.57 | 3.97 |
| Low Estimate | -1.39 | -1.61 | -6.34 | -6.19 |
| High Estimate | -0.28 | -0.12 | 0.48 | 11.81 |
| Year Ago EPS | -0.52 | -1.69 | -5.16 | -2.57 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 22 | 20 | 27 | 27 |
| Avg. Estimate | 405.78M | 432.8M | 1.83B | 2.49B |
| Low Estimate | 380.8M | 408.05M | 1.66B | 2.05B |
| High Estimate | 442.66M | 463.54M | 2B | 3.34B |
| Year Ago Sales | 229.76M | 262.98M | 1.27B | 1.83B |
| Sales Growth (year/est) | 76.60% | 64.60% | 44.20% | 36.10% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -1.37 | -1.73 | -1.53 | -1.7 |
| EPS Actual | -0.52 | -1.69 | -1.25 | -1.68 |
| Difference | 0.85 | 0.04 | 0.28 | 0.02 |
| Surprise % | 62.00% | 2.30% | 18.30% | 1.20% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.76 | -0.79 | -2.57 | 3.97 |
| 7 Days Ago | -0.76 | -0.79 | -2.57 | 3.97 |
| 30 Days Ago | -0.76 | -0.78 | -2.42 | 4.25 |
| 60 Days Ago | -0.88 | -0.82 | -1.99 | 4.34 |
| 90 Days Ago | -0.83 | -0.74 | -1.73 | 4.53 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | 3 | 3 | 2 | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | ARGX | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -46.20% | -- | -- | 8.60% |
| Next Qtr. | 53.30% | -- | -- | 11.90% |
| Current Year | 50.20% | -- | -- | 5.60% |
| Next Year | 254.50% | -- | -- | 13.20% |
| Next 5 Years (per annum) | -231.80% | -- | -- | 11.07% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Reiterates | Wedbush: Outperform to Outperform | 4/18/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 4/18/2024 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 3/27/2024 |
| Maintains | Scotiabank: Sector Perform to Sector Perform | 3/26/2024 |
| Reiterates | JMP Securities: Market Outperform to Market Outperform | 3/22/2024 |
| Maintains | Truist Securities: Buy to Buy | 3/5/2024 |
Related Tickers
IMVT Immunovant, Inc.
29.70
-0.20%
BGNE BeiGene, Ltd.
168.64
+2.55%
ASND Ascendis Pharma A/S
133.13
-0.60%
ALNY Alnylam Pharmaceuticals, Inc.
151.37
-0.60%
KRYS Krystal Biotech, Inc.
158.74
+0.67%
LEGN Legend Biotech Corporation
45.52
-0.44%
BPMC Blueprint Medicines Corporation
108.34
-0.40%
RVMD Revolution Medicines, Inc.
37.45
-2.24%
MRUS Merus N.V.
45.12
-4.18%
BBIO BridgeBio Pharma, Inc.
28.73
+3.72%